RaQualia Pharma (TSE:4579) FCF Margin %: 30.89% (As of Mar. 2026)

What is RaQualia Pharma FCF Margin %?

RaQualia Pharma TSE:4579 -2.70% 57 FCF Margin % is 30.89% as of Mar. 2026. GuruFocus rates TSE:4579 with a GF Score™ of 57/100 and a GF Value™ of 円961.31 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 947 Biotechnology companies, RaQualia Pharma ranks better than 88.81% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. RaQualia Pharma's Free Cash Flow for the three months ended in Mar. 2026 was 円248 Mil. RaQualia Pharma's Revenue for the three months ended in Mar. 2026 was 円802 Mil. Therefore, RaQualia Pharma's FCF Margin % for the quarter that ended in Mar. 2026 was 30.89%.

As of today, RaQualia Pharma's current FCF Yield % is 2.17%.

The historical rank and industry rank for RaQualia Pharma's FCF Margin % or its related term are showing as below:

TSE:4579' s FCF Margin % Range Over the Past 10 Years
Min: -101.83 Med: -32.3 Max: 49.63
Current: 19.23

During the past 13 years, the highest FCF Margin % of RaQualia Pharma was 49.63%. The lowest was -101.83%. And the median was -32.30%.

TSE:4579's FCF Margin % is ranked better than
88.81% of 947 companies
in the Biotechnology industry
Industry Median: -82.65 vs TSE:4579: 19.23

RaQualia Pharma FCF Margin % Related Terms

RaQualia Pharma FCF Margin % Historical Data

* Premium members only.

The historical data trend for RaQualia Pharma's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RaQualia Pharma FCF Margin % Chart

RaQualia Pharma Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

FCF Margin %

Get a 7-Day Free Trial

9.39

49.63

-49.48

2.09

-10.78

RaQualia Pharma Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Dec24	Mar25	Jun25	Dec25	Mar26
FCF Margin %	Get a 7-Day Free Trial															0.00	-32.20	2.84	0.00	30.89

TSE:4579 vs VRTX, REGN, ALNY: FCF Margin % Comparison

For the Biotechnology subindustry, RaQualia Pharma's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

RaQualia Pharma FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, RaQualia Pharma's FCF Margin % distribution charts can be found below:

* The bar in red indicates where RaQualia Pharma's FCF Margin % falls into.

Save Embed

57GF Score

RaQualia Pharma Inc TSE:4579

FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

RaQualia Pharma FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

RaQualia Pharma's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2025 )	/	Revenue (A: Dec. 2025 )
	=	-429.094	/	3979.956
	=	-10.78 %

RaQualia Pharma's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	247.754	/	801.993
	=	30.89 %

Frequently Asked Questions Learn more about FCF Margin % →

What does a FCF Margin % of 30.89% mean?

RaQualia Pharma (TSE:4579) has a FCF Margin % of 30.89% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on RaQualia Pharma and its competitors. According to the industry distribution chart, RaQualia Pharma ranks #106 out of 947 companies in the Biotechnology industry, placing it in the top 11.2%.

Is RaQualia Pharma's FCF Margin % too high?

RaQualia Pharma's current FCF Margin % is 30.89%. Based on the distribution chart, RaQualia Pharma ranks #106 out of 947 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, RaQualia Pharma has a GF Score™ of 57/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.

How does RaQualia Pharma's FCF Margin % compare to VRTX and REGN?

According to the Biotechnology industry distribution chart, RaQualia Pharma ranks #106 out of 947 companies for FCF Margin %. This places RaQualia Pharma in the top 11% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good FCF Margin % for a Biotechnology company?

A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high FCF Margin % mean?

A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on RaQualia Pharma and its competitors. RaQualia Pharma's current FCF Margin % is 30.89%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is RaQualia Pharma stock overvalued right now?

Based on GuruFocus' analysis, RaQualia Pharma (TSE:4579) is currently considered Significantly Undervalued. The stock's GF Value™ is 円961.31, compared to a current price of 円468.00 — trading 51.3% below its estimated fair value. The current FCF Margin % is 30.89%. RaQualia Pharma's overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is FCF Margin % calculated?

FCF Margin % is calculated from a company's financial statements. For RaQualia Pharma (TSE:4579), the current FCF Margin % is 30.89% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is RaQualia Pharma (TSE:4579) Overvalued in 2026?

Based on GuruFocus' analysis, RaQualia Pharma stock appears to be undervalued. The current stock price of 円468.00 is trading 51.3% below its estimated GF Value™ of 円961.31. GuruFocus considers RaQualia Pharma to be Significantly Undervalued.

Key valuation signals for TSE:4579:

FCF Margin %: 30.89%
GF Value™: 円961.31 vs. price of 円468.00 (51.3% below fair value)
GF Score™: 57/100 with 3 warning signs

No single metric tells the full story. See the TSE:4579 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

RaQualia Pharma Business Description

Industry Healthcare Biotechnology

Comparable Companies TSE:4978 TSE:4575 TSE:4888 TSE:4570 TSE:4896 TSE:4571 TSE:4596 TSE:7776 TSE:4564 TSE:7096 VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Address 1-21-19 Meieki Minami, Nakamura-ku, Nagoya, JPN, 470-2341

Website https://www.raqualia.co.jp

RaQualia Pharma Inc operates as a research and development-centered biotechnology company, generating revenue by creating the seeds for novel medicine and licensing them to pharmaceutical companies. The company manages the Sales and licensing of intellectual property for fundamental technologies related to pharmaceutical compounds and candidate compounds for clinical development. Its product portfolio includes, Tegoprazan (K-CAB), Galliprant and Elura both under Veterinary Medicines. The pipeline products include Potassium-Competitive Acid Blocker, Ghrelin Receptor Agonist, TRPM8 Blocker and 5-HT4 Agonist studied under different phases of development.

57GF Score

Get the complete analysis for TSE:4579

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円468.00

Price

円961.31

GF Value

View TSE:4579 Analysis

See FCF Margin % data for all stocks →